pharma · No medical condition. · Generalized Myasthenia Gravis
Anaxis Pharma
Lacuna Pharma Pty Ltd
Lacuna Pharma Pty is a pharma organization headquartered in Colmenar Viejo, AU. Primary therapeutic focus areas include No medical condition., Generalized Myasthenia Gravis, No therapeutic indication in the current trial
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2017
- Employees
- 7
- Programs
- 642
- Drugs
- 673
- Patents
- 0
CT-P1-002
Phase 2 · other · Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of septic origin or cardiogenic shock due to Acute decompensated Heart Failure
CT-P1-002 for Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of septic origin or cardiogenic shock due to Acute decompensated Heart Failure is a Phase 2 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code CT-P1-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lacuna Pharma Pty Ltd
- Phase
- Phase 2
- Modality
- other
- Indication
- Cardiogenic shock due to Acute Coronary Syndrome, cardiogenic shock of septic origin or cardiogenic shock due to Acute decompensated Heart Failure
- Status
- active
- Trials
- 1